CryoStim™ Cancer Treatment to Begin FDA Clinical Trials September 1, 2009,,Melanoma,, Jim Breitfeller

CryoStim™ Cancer Treatment to Begin FDA Clinical Trials September 1, 2009

Date:8/14/2009[“CryoStim™ represents a completely novel approach for therapeutic cancer design,” says Michael Har-Noy PhD, CEO and Chief Technical Officer. “Current therapies are not capable of eliminating every last cancer cell in the body and thus tumor recurrence is a common problem. If our experimental therapy is successful it would be possible to not only eliminate every last tumor cells, but also for the immune system to remember the tumor in order to prevent recurrence.”

Details about this cancer vaccine trial can be found at www.immunocare.net and at clinicaltrials.gov: NCT00861107. View complete details on products, trial and scientific literature at the company website.

About Immunovative:
Immunovative Therapies, Ltd. (ITL) is an Israeli-based biopharmaceutical company with US facilities in Carlsbad, California. Founded in May 2004 with financial support from Israel’s Office of the Chief Scientist, ITL is a graduate of the Misgav Venture Accelerator, a member of the world renowned Israel technological incubator program. The company was the Misgav Venture Accelerator’s candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. ITL specializes in the development of novel immunotherapy drug products that incorporate bioengineered living immune cells as the active ingredients for treatment of cancer, autoimmune and infectious disease.

Contact:
Michael Berger MD at 760-444-9040

In the Pacific Northwest contact Alan F. Hall JD at 425-774-9566



Dr. Flavell,
After 2 ½ years of stabilization from my first response to Melanoma, it appears that I may have relapsed. I will know once I have a full PET scan. My question is, why didn't my memory cells kick in? Could you help shed some light on this subject matter?

Need a copy of your paper "CD8 and T Cell Memory"

RESPONSE:

Did you receive immunotherapy ( anti-CTLA4 or PD-1 )? There are Tregs which suppress the memory responses which you may have; were immune responses measured?.The data on these Antibodies are sounding good . Contact Mario Sznol(Yale) who is a melanoma physician; I am a Ph.D so of little help on the specifics. Which paper are you referring to; we will send it.
Good Luck with all RAF

It may all come down to "BLAME IT ON THE TREGS"

So is my body making to many Tregs during activation which is shutting down the immune response? How do we block them into a normal ammount?

We need to get our hands around the Tregs.



Take Care,

Jimmy B